Quarterly ResultMay 13, 2026, 07:02 AM
Veru Reports Q2 Net Loss $2.7M; PLATEAU Trial on Track
AI Summary
Veru Inc. announced its fiscal Q2 2026 financial results, reporting a significant reduction in net loss to $2.7 million, or $0.12 per share, compared to $7.9 million, or $0.54 per share, in the prior year. The company also provided an update on its Phase 2b PLATEAU clinical study for enobosarm + semaglutide, confirming active enrollment and an interim analysis expected in Q1 2027. Cash, cash equivalents, and restricted cash increased to $27.6 million.
Key Highlights
- Q2 2026 net loss decreased to $2.7 million ($0.12/share) from $7.9 million ($0.54/share) YoY.
- Q2 2026 operating loss from continuing operations decreased to $7.2 million from $8.1 million YoY.
- Research and development expenses decreased to $3.1 million in Q2 2026 from $3.9 million YoY.
- General and administrative expenses decreased to $4.1 million in Q2 2026 from $5.2 million YoY.
- Cash, cash equivalents, and restricted cash increased to $27.6 million as of March 31, 2026.
- Phase 2b PLATEAU clinical study is actively enrolling, with interim analysis expected Q1 2027.
- Final topline data for PLATEAU study is expected in Q4 calendar year 2027.
Price Impact
More from VERU